Education
About Us
Working with TipRanks
Follow Us
Travere Therapeutics (TVTX)
NASDAQ:TVTX
Top Page
Travere Therapeutics
(NASDAQ:TVTX)
Select Model
Select Model
Rating:56Neutral
Price Target:
$35.00
▼(-3.53% Downside)
Travere Therapeutics' overall stock score reflects strong earnings call performance and positive technical indicators, offset by weak financial performance and valuation concerns. The potential FDA approval for FILSPARI is a significant positive factor, but high leverage and lack of profitability remain critical risks.
Positive Factors
Revenue Growth
Strong revenue growth from FILSPARI indicates robust demand and market penetration, supporting long-term revenue expansion and business sustainability.
Regulatory Advancements
Regulatory advancements enhance product accessibility and safety perception, potentially accelerating market adoption and competitive positioning.
Clinical Trial Success
Successful clinical trials bolster the drug's efficacy profile, improving its market potential and addressing significant unmet medical needs in kidney disorders.
Negative Factors
High Leverage
High leverage can strain financial flexibility and increase risk, potentially impacting the company's ability to invest in growth and innovation.
Profitability Challenges
Ongoing profitability challenges may hinder long-term financial health and limit resources available for strategic initiatives and R&D investments.
Negative Cash Flow
Negative cash flow can constrain operational capabilities and necessitate external financing, potentially affecting strategic flexibility and growth prospects.
Travere Therapeutics (TVTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.20B
Dividend YieldN/A
Average Volume (3M)1.60M
Price to Earnings (P/E)―
Beta (1Y)1.46
Revenue Growth114.22%
EPS Growth77.02%
CountryUS
Employees385
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.28
Shares Outstanding89,472,330
10 Day Avg. Volume1,694,264
30 Day Avg. Volume1,597,162
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)23.26
Price to Sales (P/S)5.89
P/FCF Ratio-4.06
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue5.80
Enterprise Value/Gross Profit5.94
Enterprise Value/Ebitda-111.96
Forecast
1Y Price Target
$42.89Price Target Upside18.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Travere Therapeutics Business Overview & Revenue Model
Company DescriptionTravere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
How the Company Makes MoneyTravere Therapeutics generates revenue primarily through the sale of its pharmaceutical products, particularly those that have received regulatory approval and are commercially available. The company may also earn income through partnerships with other pharmaceutical companies for co-development and commercialization of drug candidates, which can include milestone payments and royalties. Additionally, government grants and funding from research initiatives may contribute to its revenue streams. The success of Travere's revenue model heavily relies on the efficacy and market acceptance of its therapeutic products, as well as the company's ability to navigate the regulatory landscape effectively.
Travere Therapeutics Earnings Call Summary
Earnings Call Date:Oct 30, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Feb 19, 2026
Earnings Call Sentiment Positive
The earnings call reflected a strong quarter characterized by significant growth in FILSPARI sales, potential FDA approval for new indications, and successful manufacturing advancements. However, seasonal trends and a competitive market present challenges.Q3-2025 Updates
Positive Updates
FILSPARI Growth in IgA Nephropathy
FILSPARI net product sales reached approximately $91 million in the third quarter, representing an increase of more than 155% year-over-year, driven by consistent demand and deepening engagement among prescribers.
FDA Approval and Global Expansion Efforts
In August, the FDA approved a modification to the FILSPARI REMS program, simplifying care and reinforcing safety. Additionally, strong progress was made in Europe, the U.K., and Japan with regulatory approvals and trial advancements.
Potential FDA Approval for FSGS
Pending FDA approval, FILSPARI could become the first approved medication for FSGS, offering a transformative opportunity for Travere and addressing a significant unmet medical need.
Progress in Pegtibatinase Manufacturing
Successfully manufactured the first commercial scale batches of pegtibatinase, positioning for the restart of the pivotal HARMONY study in 2026.
Strong Financial Performance
Net income for the third quarter of 2025 was $25.7 million, compared to a net loss in the same period the previous year, showcasing strong financial growth.
Negative Updates
Seasonal Slowdown in New Patient Start Forms
Summer seasonality led to a reduction in the number of new patient start forms compared to previous quarters, despite strong underlying demand.
Uncertainty in Competitive Landscape
While there was no significant negative impact from competitors, ongoing market dynamics with new product launches indicate a competitive environment.
Company Guidance
During the Travere Therapeutics' Third Quarter 2025 Financial Results Conference Call, substantial progress was highlighted across multiple fronts. The company achieved approximately $91 million in net product sales for FILSPARI in the third quarter, marking a more than 155% year-over-year increase, driven by robust demand and strong physician adoption. The FDA's modification of the FILSPARI REMS program and its inclusion in the KDIGO guidelines have been pivotal, simplifying monitoring requirements and reinforcing confidence in FILSPARI's safety profile. Internationally, partners like CSL Vifor have expanded access in Europe, resulting in a meaningful market access milestone. In Japan, Renalys completed enrollment for an IgAN trial. Additionally, Travere is preparing for a potential FDA approval for FILSPARI in FSGS, which would position it as the first approved medication for this condition. The company achieved a net income of $25.7 million, with SG&A expenses increasing to $86.5 million due to preparation for the FSGS launch and continued investment in FILSPARI's commercialization.Travere Therapeutics Financial Statement Overview
Summary
Travere Therapeutics shows strong revenue growth and gross profit margins, but faces significant profitability and leverage challenges. High debt levels and negative cash flows pose financial risks, requiring careful management to achieve sustainable growth and profitability.Income Statement
Travere Therapeutics shows a strong gross profit margin of 92.69% TTM, indicating efficient cost management. However, the company faces challenges with negative net profit and EBIT margins, reflecting ongoing losses. Revenue growth is positive at 22.06% TTM, suggesting potential for future improvement, but the consistent negative margins highlight profitability issues.Balance Sheet
The company has a high debt-to-equity ratio of 12.20 TTM, indicating significant leverage and potential financial risk. Return on equity is negative, reflecting ongoing losses and challenges in generating shareholder value. The equity ratio is low, suggesting limited equity financing relative to total assets.Cash Flow
Operating cash flow and free cash flow are both negative, indicating cash burn. However, the free cash flow to net income ratio is above 1, suggesting that cash outflows are somewhat aligned with accounting losses. The negative free cash flow growth rate of -32.51% TTM highlights increasing cash flow challenges.| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 435.83M | 233.18M | 145.24M | 109.46M | 131.84M | 198.32M |
| Gross Profit | 425.49M | 225.43M | 133.79M | 105.04M | 128.02M | 192.19M |
| EBITDA | -22.58M | -265.77M | -326.25M | -299.42M | -184.46M | -145.16M |
| Net Income | -88.54M | -321.55M | -111.40M | -278.48M | -180.09M | -169.43M |
Balance Sheet | ||||||
| Total Assets | 538.58M | 594.13M | 788.91M | 672.59M | 776.63M | 607.44M |
| Cash, Cash Equivalents and Short-Term Investments | 254.53M | 370.70M | 566.85M | 450.25M | 552.88M | 361.59M |
| Total Debt | 329.75M | 401.58M | 404.78M | 407.49M | 261.99M | 244.03M |
| Total Liabilities | 465.02M | 535.05M | 588.10M | 629.73M | 474.52M | 396.23M |
| Stockholders Equity | 73.56M | 59.08M | 200.81M | 42.85M | 302.11M | 211.21M |
Cash Flow | ||||||
| Free Cash Flow | -80.33M | -338.69M | -321.61M | -214.66M | -38.94M | -162.59M |
| Operating Cash Flow | -58.61M | -237.47M | -280.02M | -186.29M | -14.79M | -42.74M |
| Investing Cash Flow | 52.42M | 99.33M | 55.78M | -32.55M | -137.62M | -61.33M |
| Financing Cash Flow | 78.97M | 139.42M | 218.75M | 117.57M | 231.68M | 127.71M |
Travere Therapeutics Technical Analysis
Neutral
36.28
Price Trends
35.09
Positive
29.17
Positive
22.91
Positive
Market Momentum
0.89
Positive
50.28
Neutral
28.13
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TVTX, the sentiment is Neutral. The current price of 36.28 is below the 20-day moving average (MA) of 36.42, above the 50-day MA of 35.09, and above the 200-day MA of 22.91, indicating a neutral trend. The MACD of 0.89 indicates Positive momentum. The RSI at 50.28 is Neutral, neither overbought nor oversold. The STOCH value of 28.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TVTX.
Travere Therapeutics Risk Analysis
Travere Therapeutics disclosed 59 risk factors in its most recent earnings report. Travere Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Travere Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $3.58B | -83.44 | -28.17% | ― | 129.21% | 80.35% | |
60 Neutral | $3.39B | -38.78 | -28.35% | ― | 182.44% | 47.21% | |
56 Neutral | $3.20B | -33.45 | -410.78% | ― | 114.22% | 77.02% | |
52 Neutral | $2.37B | -2.69 | -91.06% | ― | -32.98% | -18.46% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $2.92B | -15.11 | -34.78% | ― | ― | -34.96% | |
47 Neutral | $2.15B | -4.44 | -16.45% | ― | ― | ― |
* Healthcare Sector Average
TVTX
Travere Therapeutics
36.28
18.19
100.55%
GLPG
Galapagos
33.04
7.39
28.81%
ARQT
Arcutis Biotherapeutics
29.58
15.77
114.19%
IRON
Disc Medicine
80.94
21.70
36.63%
TARS
Tarsus Pharmaceuticals
78.08
25.39
48.19%
RXRX
Recursion Pharmaceuticals
4.86
-2.02
-29.36%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.